SCHEMBL20516341

SCHEMBL20516341

CC(C)(C)OC(=O)N1CCN(c2cccc(-c3ccnc(Cl)n3)c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.53
CKS1B P61024 2/20 0.48
SKP1 P63208 2/20 0.48
SKP2 Q13309 2/20 0.48
PDE4D Q08499 1/20 0.48
GPR119 Q8TDV5 4/20 0.47
MAPT P10636 1/20 0.47
POLB P06746 1/20 0.47
JAK2 O60674 1/20 0.47
JAK3 P52333 1/20 0.47
SUV39H2 Q9H5I1 1/20 0.45
PIK3CA P42336 1/20 0.45
ACHE P22303 2/20 0.45
KIT P10721 2/20 0.44
DGAT1 O75907 1/20 0.44
SMARCA2 P51531 1/20 0.44
SMARCA4 P51532 1/20 0.44
PBRM1 Q86U86 1/20 0.44
ABCB1 P08183 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30791110 1.00 ADORA2A (0.53) ADORA2ACKS1BSKP1SKP2PDE4D
SCHEMBL3753329 0.87 CKS1B (0.45) ADORA2ACKS1BSKP1SKP2GPR119
SCHEMBL3760202 0.84 EGLN2 (0.52) CKS1BSKP1SKP2GPR119MAPT
SCHEMBL902759 0.82 ADORA2A (0.60) ADORA2ACKS1BSKP1SKP2PDE4D
SCHEMBL1467354 0.82 ALDH1A1 (0.52) GPR119MAPTPOLB
SCHEMBL16933561 0.82 GPR119 (0.54) ADORA2ACKS1BSKP1SKP2GPR119
SCHEMBL6950816 0.81 RET (0.54) CKS1BSKP1SKP2GPR119
SCHEMBL20516119 0.81 JAK2 (0.53) ADORA2AJAK2JAK3KIT
SCHEMBL30791072 0.81 JAK2 (0.53) ADORA2AJAK2JAK3KIT
SCHEMBL3268748 0.81 CKS1B (0.56) ADORA2ACKS1BSKP1SKP2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110799190-B Heterocyclic compounds 卡都瑞恩医药有限公司 2024-04-19 CN disclosed
CN-113365632-B Aminopyrimidine compounds 卡都瑞恩医药有限公司 2024-03-08 CN disclosed
EP-3856188-B1 AMINOPYRIMIDINE COMPOUND CARDURION PHARMACEUTICALS INC (US) 2023-06-21 EP disclosed
US-20220112184-A1 AMINOPYRIMIDINE COMPOUND CARDURION PHARMACEUTICALS, LLC 2022-04-14 US disclosed
US-11197858-B2 Substituted amines for treating cardiac diseases CARDURION PHARMACEUTICALS, LLC (US) 2021-12-14 US disclosed
US-11130752-B2 Aminopyrimidine compound CARDURION PHARMACEUTICALS, LLC (US) 2021-09-28 US disclosed
CN-113365632-A Aminopyrimidine compounds 卡都瑞恩医药有限责任公司 2021-09-07 CN disclosed
EP-3856188-A1 AMINOPYRIMIDINE COMPOUND Cardurion Pharmaceuticals, LLC (US) 2021-08-04 EP disclosed
US-20200230137-A1 SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES CARDURION PHARMACEUTICALS, LLC (US) 2020-07-23 US disclosed
WO-2020068854-A1 AMINOPYRIMIDINE COMPOUND CARDURION PHARMACEUTICALS, LLC (US) 2020-04-02 WO disclosed
WO-2020068846-A1 HETEROCYCLIC COMPOUND HETEROCYCLIC COMPOUND (US) 2020-04-02 WO disclosed
US-20200095240-A1 AMINOPYRIMIDINE COMPOUND CARDURION PHARMACEUTICALS, LLC 2020-03-26 US disclosed
CN-110799190-A Heterocyclic compounds 卡都瑞恩医药有限责任公司 2020-02-14 CN disclosed
EP-3600327-A1 HETEROCYCLIC COMPOUND Cardurion Pharmaceuticals, LLC (US) 2020-02-05 EP disclosed
US-10543212-B2 Substituted amines for treating cardiac diseases CARDURION PHARMACEUTICALS, LLC (US) 2020-01-28 US disclosed
US-20180280389-A1 HETEROCYCLIC COMPOUND CARDURION PHARMACEUTICALS, LLC (US) 2018-10-04 US disclosed
WO-2018183112-A1 HETEROCYCLIC COMPOUND CARDURION PHARMACEUTICALS, LLC (US) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11130752-B2 Aminopyrimidine compound CALM1, CAMK4, CAMK2B ADORA2A 1034/4885CKS1B 921/4885SKP1 226/4885
US-11197858-B2 Substituted amines for treating cardiac diseases TNNI3, CALM1, CAMK2G ADORA2A 709/4885CKS1B 1334/4885SKP1 911/4885
US-20180280389-A1 HETEROCYCLIC COMPOUND CALM1, CAMK2B, CAMK2G ADORA2A 2382/4885CKS1B 1196/4885SKP1 241/4885
US-20200095240-A1 AMINOPYRIMIDINE COMPOUND CALM1, CAMK4, CAMK2B ADORA2A 1034/4885CKS1B 921/4885SKP1 226/4885
US-10543212-B2 Substituted amines for treating cardiac diseases TNNI3, CALM1, CAMK2G ADORA2A 709/4885CKS1B 1334/4885SKP1 911/4885
US-20200230137-A1 SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES TNNI3, CALM1, CAMK2G ADORA2A 709/4885CKS1B 1334/4885SKP1 911/4885
US-20220112184-A1 AMINOPYRIMIDINE COMPOUND CALM1, CAMK4, CAMK2B ADORA2A 1034/4885CKS1B 921/4885SKP1 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.